Primerdesign and Origin Sciences Collaborate on Breakthrough Rectal Mucus DNA Extraction for Early Cancer Detection

Primerdesign and Origin Sciences partner to optimize DNA extraction from rectal mucus, enhancing early detection and monitoring of gastrointestinal diseases.

By: AXL Media

Published: Mar 25, 2026, 5:51 AM EDT

Source: Information for this report was sourced from Primerdesign

Revolutionizing Gastrointestinal Diagnostics Through Mucosal Analysis

The diagnostic landscape for gastrointestinal diseases is shifting toward more representative biospecimens as Primerdesign and Origin Sciences announce a strategic technical partnership. Traditional methods for monitoring gut health have long relied on stool or blood samples, which often provide an incomplete picture of the colon's molecular state. By focusing on rectal mucus, this new collaboration seeks to leverage a unique biological source that contains cells and molecular signals shed from the entire lining of the large intestine, potentially offering a more comprehensive view of patient health than previous methodologies allowed.

The Engineering of a High-Yield Extraction Protocol

At the center of this partnership is the development of a custom workflow designed to overcome the inherent challenges of processing mucosal tissue. Origin Sciences utilizes a patented medical device known as OriCol™, which facilitates the rapid and minimally invasive collection of rectal mucus. To transform this raw biological material into actionable data, Primerdesign has applied its expertise in nucleic acid extraction via its exsig® Mag product range. The resulting protocol is engineered to deliver consistent performance and high DNA yields, ensuring that the genetic material recovered is of sufficient quality for sensitive downstream molecular applications.

Addressing the Limitations of Traditional Sampling

Historically, the investigation of colorectal cancers and advanced adenomas has been hindered by the limitations of available sampling techniques. Stool samples can be inconsistent in their cellular content, while blood tests may not capture localized early-stage signals effectively. Rectal mucus, however, serves as a diverse and stable reservoir for biomarkers, making it uniquely suited for the earliest detection of gastrointestinal disease. This specialized biospecimen is also being evaluated for its utility in residual disease monitoring and the selection of targeted treatments for patients already undergoing therapy.